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David H FarbDavid H Farb is Professor and Chair of the Department of
Pharmacology and Experimental Therapeutics at Boston
University School of Medicine. Dr. Farb is Principal Inves-
tigator and Director of the Laboratory of Molecular
Neurobiology and Director of the university-wide NIGMS
training program in Biomolecular Pharmacology. A re-
nowned neuropharmacologist, his research integrates
existing electrophysiological, behavioral, pharmaco-
logical, and molecular genetics technologies in a novel
systems-level platform to establish a molecular dissec-
tion of spatial memory. In this interview we find out a
little more about the key issues in this field of research.Could you tell us about the career path that led
you to your current position and research
interests?
I suppose anxiety was one of the early motivators in my
career; more specifically, the study of the role of GABAA
receptors in the development of anxiety disorders, ran-
ging from generalized anxiety to post-traumatic stress.
As a post-doctoral fellow, I worked with then MD/PhD
student Dennis W. Choi and Gerald D. Fischbach in
the Department of Pharmacology at Harvard Medical
School to uncover the cellular mechanisms of action of
benzodiazepines-the class of agents that serve not only
as anxiolytics, but sedative hypnotics and anticonvul-
sants as well. We showed that benzodiazepines act by
positive allosteric modulation of GABAA receptors [1],
and we provided the first measurement of the synthesis,
degradation and turnover of a neurotransmitter receptor
in the central nervous system [2]. My research today con-
tinues to be primarily focused on the discovery and devel-
opment of neuromodulators as therapeutic agents, and on
the structure, function, and cellular dynamics of ion chan-
nels and receptors in the brain and spinal cord [3]. For ex-
ample, we have shown that the endogenous neuroactiveCorrespondence: dfarb@bu.edu
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reproduction in any medium, provided the orsteroid pregnenolone sulfate, which is formed from choles-
terol via sulfotransferase action on pregnenolone, creates a
branch point for activation of an allosteric modulator of
NMDA and non-NMDA glutamate receptor function [4].
We have recently reported that this unique sulfated ster-
oid can stimulate the trafficking of functional NMDA re-
ceptors to the cell surface via a non-canonical G-protein
and Ca++-dependent mechanism, a finding that may fur-
ther the development of treatments not only for schizo-
phrenia, but also for other conditions associated with
malfunctioning NMDA receptors, such as age-related de-
creases in memory and learning ability [5].What are your aspirations for the ‘Basic
Pharmacology’ section of BMC Pharmacology and
Toxicology?
In recent years, open access journals have become ex-
tremely influential in shaping the exchange of scientific
knowledge, and BMC Pharmacology and Toxicology has
been in the forefront of this educational endeavor. In
particular, the journal has played a major role in facili-
tating the timely publication of new scientific research,
creating an open forum for discussion of current re-
search trends, and enabling a versatile platform for pub-
lication of research findings. My aspirations for the
‘Basic Pharmacology’ section are to continue this timely
direction of the journal, publishing translational con-
tent that reflects emergent trends in biomedical re-
search and bridges the fields of pharmacology, clinical
pharmacology and toxicology. To this end, we encour-
age submission of research reports in all therapeutic
areas broadly encompassing pharmacology and signal-
ing, with incorporation of basic science drug discovery
and translational medicine. We are also enthusiastic in
our goal to disseminate research that incorporates existing
and rapidly evolving leading edge technologies to bridge
systems-level inquiries with those at the cellular and mo-
lecular levels, as well as research such as computational
modeling of systems based on technology platforms thats is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease [6].
We are also striving to balance two competing, but not
diametrically opposed, forces in scientific publishing: “pres-
tige” science versus less trendy but still exciting and, ideally,
solid science. Clearly, citation rates are a useful indicator for
measuring the interest given to a publication over a mean-
ingful period of time. It is important to recognize, however,
that the growing emphasis on impact factors in scientific
publishing is problematic [7,8], and trendiness rather than
reproducibility is being misused by some to guide merit rat-
ings awarded by NIH and other funding agency review
panels and may be a driver of the disturbingly high rate of
failure, more than 50%, to reproduce findings reported in
some high impact journals. Scientists at Amgen reported
that they could reproduce the key results of only a small
fraction (11%) of 53 publications (many in high impact
journals) they attempted to validate [9]. As communica-
tors of factual information, it is our responsibility to look
through the prism of time, trying ever to focus on the pro-
gress of science. For this reason, the open access format of
BMC Pharmacology and Toxicology may serve to counter-
balance the pressures on scientists by focusing more on
solid science. We intend to be nimble, staying on the lead-
ing edge of translational and basic research through a pol-
icy of openness to new ideas that are supported by
convincing, reproducible evidence.
Which areas of research would you be particularly
interested in seeing submitted to your section?
It’s about publishing all of the science that’s fit to digitize,
to spin a phrase. I believe our readership would benefit
from research that explores the increasingly pivotal role of
personalized medicine in the development of more precise
therapeutic approaches to a range of diseases. Genome-
wide association studies have enabled a greater under-
standing of individual differences in disease susceptibility,
age of onset, and sexual differentiation in the response to
treatment, and greatly underscore the need for an expan-
sion of these types of approaches. For example, it would
be of interest to assess how, or even whether, antiviral
therapeutics differentially affect the responsiveness of fe-
male patients to treatment for sexually transmitted dis-
eases. I am particularly interested in seeing research that
embraces new technologies to facilitate in-depth scientific
inquiry in any area of pharmacological sciences.
What challenges currently exist in the field of
pharmacology?
Despite intense drug discovery efforts, disorders of the
central nervous system have suffered the most from a lack
of newly developed therapeutics. Target-based drug dis-
covery, or the process of identifying a drug candidate that
acts at a validated target molecule, is the most widely usedapproach. Although this approach has been successful in
identifying drugs for previously validated targets, it has been
less successful when novel targets are involved. This is espe-
cially true in neuropsychiatric disorders with multifaceted
etiologies, and we should consider that a systems-level ap-
proach will be needed to model these disease states.
Renewed efforts to identify allosteric modulators of multiple
receptor types (G protein-coupled receptors in particular)
are expected to yield rich dividends in the near future [10].
Several of these compounds have progressed to clinical tri-
als. One promising therapeutic approach has been the devel-
opment of allosteric modulators, which target a site that is
distinct from orthosteric agonist binding. Allosteric positive
modulators targeting the benzodiazepine binding site of
GABAA receptors are a classic example of early successes
utilizing this approach [1,11]. These compounds are pre-
scribed frequently for the treatment of anxiety disorders,
epilepsy, and insomnia, as well as pre-anesthetic sedation
and muscle relaxation. Although recent advances in under-
standing receptor subtype pharmacology in rodent models
hold great promise for understanding the biology of drug ac-
tion, the science of translation to humans remains a conun-
drum, as evidenced by the failure of research in mouse
transgenic models to form a platform for the translation of
pharmacological effects in mouse models into anxiolytics for
use in human [12]. Breaking the barrier of translational sci-
ences is the single greatest challenge for modern pharmacol-
ogy, as a whole new pharmacopeia awaits discovery!
Another key challenge in pharmacology is optimizing
the use of the ever-increasing amount of genetic informa-
tion available to us. While the Human Genome Project
was rightly heralded as a milestone by those who referred
to it as a new platform for aiding medical research, it is
nonetheless misleading to think of it as a “roadmap” as we
normally understand the term. The genotype may identify
a particular phenotype, but does not guide us in one direc-
tion or another therapeutically, at least at this time; rather,
it provides clues to a complex roadway of potential thera-
peutic targets [13]. In this respect, BMC Pharmacology
and Toxicology can provide a useful venue for communi-
cating broad-ranging advances that bridge molecular iden-
tities with clinical endpoints without having to assert
claims to having solved the problem. We welcome the ex-
citement of the discovery process!
How might these challenges be met by future
research efforts?
Endeavors to develop allosteric modulators are com-
plemented by drug discovery efforts incorporating a multi-
tude of innovative approaches. A prime example is the use
of designer receptors to aid in deciphering the involvement
of specific receptors and transmitters in disease [14]. The
close scrutiny of protein-protein interactions, combined
with innovative methods of generating protein structure-
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ceptors and intracellular signaling moieties, holds promise
for generating novel molecular probes that are useful both
as research tools and as future therapeutics. A greater em-
phasis on structure-based drug discovery studies aided by
computational and structural modeling efforts bodes well
for future success. In fact, computational and structural
modeling studies are of great importance not only in drug
design, but also in understanding the mechanistic under-
pinnings of various disorders ranging from autism and
post-traumatic stress disorder to angina and hypertension.
What recent advances in the field of
pharmacology have particularly interested you?
There are several fields that I think are of particular
promise moving forward, including molecular genetics,
nanomedicine, optogenetics, tissue engineering, and
stem cell technology. To start with genetics as an ex-
ample, Cre-mediated genetic manipulation in animal
models is likely to be of great utility in querying recep-
tor involvement in various disease states and identifying
relevant signaling cascade entities. In addition, remark-
able progress has been achieved in understanding the
significance of microRNAs (miRNA) in the regulation
of multiple physiological and pathological conditions.
The successful use of antagomirs (a novel class of synthetic
oligonucleotides that inhibit miRNAs) in clinical applica-
tions for cancer treatment highlights the impact that this
class of small RNAs is likely to have on diagnostics and
therapeutics in the future [15,16]. Epigenetic studies are in-
creasingly utilized to aid in the identification of novel thera-
peutic targets in a wide variety of diseases. I also mentioned
optogenetics, which affords a means of regulating neuronal
activity by expression of bacterial light-sensing molecules in
a nucleus of choice in the brain, doing so in a cell- and
pathway-specific manner. This novel technology is shedding
light on targets for various disorders, while remaining mind-
ful that existing methods may not report responsivity of
neurons accurately, yet in the future may itself yield novel
options for discovery science to utilize [17]. Recent advances
in tissue engineering and stem cell-based therapeutics also
offer tremendous potential for treating disease and identify-
ing new drugs. However, this field is not without limitations
and challenges. Identifying extracellular entities and mo-
lecular remodeling mechanisms that regulate stem cell dif-
ferentiation is crucial for the treatment or amelioration of
multiple diseases and brain disorders. Cellular reprogram-
ming and generation of inducible pluripotent stem cells
from adult cell types aids in creating patient-specific stem
cells. These disease-relevant cell types provide a novel
means of modeling specific diseases and identifying rele-
vant pathways, biomarkers and treatments. Disorders ran-
ging from cardiovascular to psychiatric pathologies such
as schizophrenia are benefiting from this approach.Where might new technologies assist with
advances in the field of pharmacology?
Toxicity is still the major obstacle in drug development,
and overcoming this obstacle will require the develop-
ment of more streamlined in silico or in vitro toxicology
workflows. The importance of biomarkers, both as diag-
nostics of disease and as indicators of toxicity associated
with drug treatments, cannot be over emphasized. In
addition, drug delivery continues to be hindered by the
inability of targeted therapeutics to cross various cellu-
lar barriers, such as the blood-cancer cell cluster barrier
or the blood–brain and blood-nerve fiber barriers. New
technologies-including nanotechnology/nanomedicine,
in silico drug screening, and biophysical research on
barrier surfaces-are crucial for addressing these limita-
tions to drug delivery. The importance of translational
studies in pharmacology is underscored by the federal
endorsement of translational studies, as evidenced by
the recent launching of a National Center for Advan-
cing Translational Sciences (NCATS) [18] in partner-
ship with eight major pharmaceutical companies [18].
To achieve an all-inclusive or interdisciplinary pharma-
cological sciences journal has been a challenge for gen-
erations – to do this in a meaningful and useful way will
require the participation of our readership who will
after all support the task of peer review.
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